Nymox Announces Validation by the European Member States of European Marketing Authorization Application for Fexapotide Triflutate for Benign Prostatic Hyperplasia
September 14, 2017:
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce today that the European Member States for Nymox’s Marketing Authorization Application (MAA) for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH, prostate enlargement) have accepted the Company’s MAA.
September 11, 2017:
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) The September 16 AUA Meeting in Amelia Island, Florida has been postponed due to the hurricane disaster in Florida.
August 9, 2017:
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce recent completion of private placements with proceeds totaling US $3.0 million.
Nymox Announces Symposium for Company’s BPH Drug at American Urological Association Meeting in September
August 7, 2017:
Nymox Pharmaceutical Corporation is pleased to announce that an important large symposium and panel assessment of the Company’s new drug Fexapotide Triflutate will be held at the September meeting of the American Urological Association, MidAtlantic Section.
Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials
May 31, 2017:
Nymox Pharmaceutical Corporation is pleased to announce statistically significant clinical trial results showing that the Companys prostate enlargement (BPH) and prostate cancer drug Fexapotide Triflutate produced clinically important improvements in sexual function in first-line patients who received Fexapotide in the Companys U.S. long-term clinical trials.
May 10, 2017:
Nymox Pharmaceutical Corporation will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079).
NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT
May 8, 2017:
Following Nymoxs announcement of the Companys filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EST on Wednesday May 10, 2017.
May 3, 2017:
May 3, 2017: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain.
March 29, 2017:
Nymox Pharmaceutical Corporation provided an update today on the Companys development activities for Fexapotide Triflutate, its new drug for prostate enlargement.
Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy
November 29, 2016:
Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy results as early as 10 days compared to control patients who received placebo or who had prior history of other BPH medical treatments.